Creative Touch Permanent Makeup and Aesthetics

Serine palmitoyltransferase (SPT) is the enzyme that commits the cell to ceramide synthesis – combining serine and palmitoyl- CoA to produce the sphingoid base from which all ceramide subtypes derive. As the rate-limiting step, SPT determines the ceiling on ceramide production regardless of what happens downstream. In keratinocytes, SPT operates within a ceramide-sensing feedback loop: ORMDL proteins physically bind SPT and suppress its activity when ceramide levels are adequate, releasing the brake when ceramide falls. This homeostatic system partially compensates for mild depletion but fails when suppression signals – oestrogen decline (specifically SPTLC2), cortisol elevation, IL-13/STAT6 cytokine activity, or elevated ORMDL3 expression associated with atopic susceptibility – override the feedback threshold. Niacinamide upregulates SPTLC2 directly. Microneedling upregulates SPTLC3 through the wound-healing keratinocyte differentiation cascade. Omega-3 fatty acids and oral phytoceramides provide complementary upstream and bypass routes that restore SPT capacity in resistant presentations.

Serine palmitoyltransferase (SPT) catalyses the condensation of serine and palmitoyl-CoA to produce 3-ketodihydrosphingosine – the sphingoid base precursor from which all ceramide subtypes in human skin ultimately derive. As the committed, rate-limiting step in sphingolipid biosynthesis, SPT activity sets the upper limit on ceramide production regardless of downstream enzyme availability. It is not merely a switch that is either on or off, however: SPT operates within a dynamic feedback system, continuously adjusting output to the ceramide status of the tissue it serves. Understanding that regulatory architecture explains both why the skin can partially self-correct mild ceramide shortfalls and why certain clinical presentations are so resistant to surface-level intervention alone.

Subunit Structure: Why the Same Enzyme Produces Different Ceramides

SPT in mammalian skin is a heterotrimer of SPTLC1, SPTLC2, and SPTLC3 subunits. SPTLC1 forms the structural scaffold. SPTLC2 and SPTLC3 carry the catalytic activity and differ critically in their preferred fatty acyl-CoA substrates. ^{[5] [3]}

• SPTLC2 preferentially uses palmitoyl-CoA (C16), generating the C18 sphingoid bases that dominate the ceramide composition of adult skin.
• SPTLC3 preferentially uses myristoyl-CoA (C14), generating C16 sphingoid bases – shorter chains that pack less tightly in the lamellar matrix.

Human skin expresses unusually high levels of SPTLC3 relative to other tissues – a characteristic that makes skin’s ceramide profile particularly sensitive to any stimulus that differentially affects subunit expression. This subunit distinction is not a biochemical detail but a clinically meaningful one: the ceramide chain-length distribution in any given skin state reflects which subunit is most active, and chain-length shortening is one of the earliest markers of barrier deterioration. ^[12]

The ORMDL Feedback System: SPT as a Ceramide Sensor

SPT does not synthesise ceramide unchecked. The ORMDL proteins (ORMDL1, ORMDL2, ORMDL3) form stable regulatory complexes with SPT and function as its homeostatic brake – directly suppressing SPT activity when ceramide levels are adequate. ^[1]

Cryo-EM structural work published in Nature Communications (2023) resolved the mechanism precisely: ceramide binds to a specific site on the ORMDL3 N-terminus, stabilising an inhibitory conformation that physically blocks palmitoyl-CoA from accessing the catalytic site of SPT, reducing both the maximum synthesis rate (Vmax) and the enzyme’s affinity for its substrate. When ceramide levels fall below the feedback threshold, ORMDL inhibition is released and SPT activity increases. ^[10]

This homeostatic architecture explains a pattern frequently seen in clinic: skin with mild ceramide depletion partially compensates, particularly in younger or pre-menopausal presentations where the suppression signals are not yet dominant. The feedback loop is intact and responsive. In presentations where multiple suppression signals are operating simultaneously – oestrogen decline, elevated cortisol, and type 2 cytokine activity together – the compensatory upregulation is insufficient to overcome the combined suppressive load, and the ceramide shortfall becomes self-sustaining.

Clinical Pearl
The ORMDL feedback system also means that providing ceramides topically has a ceiling effect on stimulating endogenous synthesis – a well-replenished barrier will maintain ORMDL-mediated SPT suppression. This is not a reason to avoid topical ceramides, but it is why the combination of topical supply and SPT upregulation (via niacinamide) produces more complete barrier recovery than either alone: niacinamide acts upstream of the feedback system at the transcriptional level.

ORMDL3, Atopic Susceptibility, and Ceramide Depletion

ORMDL3 is one of the most robustly replicated genetic susceptibility loci for both atopic dermatitis and asthma in genome-wide association studies. Its physiological role is as a negative regulator of SPT, reducing de novo ceramide synthesis. In atopic-susceptible individuals, chronically elevated ORMDL3 expression tips the SPT/ORMDL stoichiometry toward suppression, reducing the ceramide synthesis capacity that the ORMDL feedback system was designed to modulate. ^[6]

This provides a genetic architecture explanation for the persistent co-occurrence of atopic susceptibility and ceramide depletion. The same gene variant that confers atopic risk directly suppresses SPT – meaning ceramide deficiency in atopic-tendency skin is not simply a consequence of inflammation but partly a primary, genetically encoded suppression of the synthesis enzyme. In these clients, the inflammatory environment ( IL-4/IL-13/STAT6 suppression) and genetic ORMDL3 elevation are acting on SPT through two independent routes simultaneously. Treatment approaches that address only the inflammatory route leave the genetic suppression component unaddressed.

What Suppresses SPT: The Clinical Landscape

Oestrogen decline: Primary human keratinocyte research confirms that oestradiol (10 nM) directly increases ceramide production, specifically upregulating CER[NS] with C18 sphingoid bases – the product of SPTLC2 activity. CER[NS] with C16 bases (the SPTLC3 product) was not consistently upregulated, confirming that oestrogen’s primary SPT effect operates through SPTLC2 specifically. Post-menopausal skin shows ceramide reductions alongside chain-length shortening that are substantially prevented by hormone replacement therapy – changes in the ceramide profile that map directly onto reduced SPTLC2 activity. The C18-chain ceramides that oestrogen supports are among those that pack most tightly in the lamellar matrix; their selective decline contributes to the orthorhombic-to-liquid crystal packing transition that increases barrier permeability in post-menopausal skin before any visible skin change is apparent. ^[12]

Cortisol: Chronically elevated cortisol impairs ceramide synthesis through HPA-axis-mediated stress signalling (independent of the IL-4/IL-13 route) while simultaneously inhibiting HMG-CoA reductase (reducing cholesterol synthesis). The two stress-mediated effects act on different enzymes but produce coordinated collapse across all three stratum corneum lipid classes.

IL-13 via STAT6: The cytokine pathway suppresses both SPT (ceramide synthesis) and ELOVL4 (very long-chain fatty acid elongation for acylceramides) in a coupled failure. This is the mechanism by which the inflammatory environment in atopic and sensitised skin depletes ceramide at the synthesis root rather than through accelerated breakdown.

Elevated ORMDL3: As above – the genetic route that operates independently of all three hormonal and inflammatory routes, and that is not resolved by anti-inflammatory treatment alone.

What Upregulates SPT

Niacinamide directly upregulates SPTLC2 at the mRNA level, confirmed in the Tanno et al. research showing increased LCB1 and LCB2 expression alongside the 4× ceramide synthesis increase at seven days. Because niacinamide acts transcriptionally on SPTLC2, it operates upstream of the ORMDL feedback system and can increase synthesis capacity even when the feedback brake is partially engaged. ^[8]

Microneedling upregulates SPTLC3 through the wound-healing keratinocyte differentiation cascade. During active keratinocyte differentiation, lamellar body biogenesis and lipid synthesis are at peak activity. The SPTLC3 upregulation documented in microneedling research reflects activation of the full differentiation programme of which ceramide synthesis is a component. ^[7]

Barrier perturbation – including tape stripping, surfactant challenge, and UVB exposure – upregulates SPT as part of the skin’s homeostatic repair response. UVB specifically increases LCB2 (SPTLC2) mRNA and protein in keratinocytes, driving increased sphingolipid synthesis as a repair signal. This is mechanistically distinct from UVB’s longer-term inflammatory and photoageing effects: the acute SPT upregulation is a defence response that partially compensates for UV-driven barrier disruption in the short term, and that becomes progressively less effective as chronic UV exposure accumulates inflammatory suppression on top of it. ^[2]

Resolving the IL-4/IL-13 environment via CAP, polynucleotides, or omega-3 modulation lifts STAT6-mediated SPT suppression, restoring synthesis capacity that was actively inhibited rather than simply declining.

Complementary Routes: Omega-3 PPAR-α Coordination and Phytoceramide Salvage

Omega-3 fatty acids ( EPA/ DHA) activate PPAR-α, which transcriptionally coordinates SPT and downstream ceramide synthesis enzymes while simultaneously lifting IL-4/IL-13 suppression. This provides a dual systemic route that restores SPT capacity in clients with combined hormonal and inflammatory suppression. ^[9]

Oral phytoceramides bypass SPT de novo suppression entirely via the salvage pathway: exogenous plant-derived sphingoid bases are absorbed intact in the small intestine and directly incorporated into stratum corneum ceramides without requiring the SPT step. This is particularly valuable for clients with genetic ORMDL3 elevation or multi-route SPT inhibition where endogenous de novo capacity is limited. ^{[4] [11]}